This study evaluated the combined effects of oxylanthanum carbonate (OLC), an investigational phosphate binder, and tenapanor, an approved sodium/hydrogen exchanger 3 (NHE3) inhibitor that reduces paracellular phosphate absorption, on urinary phosphate excretion in rats on a high phosphorus diet. Sixty-four male Sprague Dawley rats were randomized into eight groups: vehicle; tenapanor (0.15 mg/kg) only; OLC (0.75%, 1.5%, and 3%) only; and combination OLC (0.75%, 1.5%, and 3%) + tenapanor (0.15 mg/kg). Vehicle and tenapanor were dosed orally twice/day whereas OLC was incorporated into diets. We collected 24-hour urine samples to measure urinary phosphate excretion, a proxy for intestinal phosphate absorption efficiency. Primary analyses compared pooled results in the three OLC dose groups. In the tenapanor 0.15 mg/kg group, mean urinary phosphate excretion from Days 9 to 11 was 8.5 mg/day (12.5%) lower compared to the vehicle group. In the OLC alone groups, mean urinary phosphate excretion (pooled across the 0.75, 1.5, and 3% OLC dose groups) was 12 mg/day (17.7%) lower compared to the vehicle group. Compared to vehicle, urinary phosphate excretion was 28.0 mg/day (41.3%) lower in the combination OLC + tenapanor groups (p=0.016). Bliss model of independence assessing the statistical significance between observed and predicted results indicated that combination OLC + tenapanor was synergistic (p=0.009 for 0.75% OLC + tenapanor and p=0.010 for 1.5% OLC + tenapanor). In summary, we demonstrated sizeable reductions in urinary phosphate excretion in response to OLC monotherapy and the most pronounced reductions in urinary phosphate excretion when using OLC in combination with tenapanor.
Read full abstract